Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17132793 | NUCLEIC ACID-DRUG COMPLEX AND USE THEREOF | December 2020 | January 2023 | Allow | 24 | 1 | 1 | No | No |
| 17127581 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | December 2020 | August 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17110525 | Preparation and Use of Sugar-targeting Nanoparticles for Modifying SiRNA | December 2020 | February 2024 | Allow | 39 | 1 | 1 | No | No |
| 17110121 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | December 2020 | January 2021 | Allow | 2 | 0 | 0 | No | No |
| 17090596 | APTAMER FIBERS | November 2020 | August 2022 | Abandon | 21 | 2 | 0 | No | No |
| 17086616 | MAMMALIAN CELLS FOR PRODUCING A SECRETED PROTEIN | November 2020 | September 2022 | Allow | 22 | 1 | 0 | No | No |
| 17076696 | TAILORED MODULATION OF GENE REGULATION PROGRAMS VIA FUNCTIONAL ENHANCER RNA | October 2020 | August 2023 | Allow | 34 | 2 | 0 | No | No |
| 17073163 | NOVEL SHORT HAIRPIN RNA COMPOSITIONS, METHODS OF MAKING AND APPLICATIONS THEREOF | October 2020 | May 2023 | Allow | 31 | 2 | 1 | No | No |
| 17071685 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | October 2020 | March 2021 | Allow | 5 | 1 | 0 | No | No |
| 17046124 | MICRORNA-BASED COMPOSITIONS AND METHODS USED IN DISEASE TREATMENT | October 2020 | March 2023 | Allow | 30 | 1 | 1 | No | No |
| 17045426 | MODULATORS OF EZH2 EXPRESSION | October 2020 | February 2022 | Allow | 16 | 0 | 0 | Yes | No |
| 17039075 | USES FOR PREVENTION OR TREATMENT OF BRAIN DISEASES USING MICRORNA | September 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 17036369 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BETA-CATENIN-ASSOCIATED DISEASE OR DISORDER | September 2020 | July 2022 | Allow | 22 | 1 | 1 | No | No |
| 16982787 | METHODS FOR MODULATING FMR1 EXPRESSION | September 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 17025345 | EXOSOMAL MICRORNA IN SERUM AS AN INDICATOR FOR THE ACTIVATION OF BROWN AND BEIGE FAT TISSUE (BAT) | September 2020 | January 2023 | Allow | 28 | 1 | 1 | No | No |
| 16981329 | METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULE | September 2020 | October 2023 | Allow | 37 | 1 | 1 | No | No |
| 17016021 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | September 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 16978815 | METHODS FOR TREATING OVARIAN CANCER | September 2020 | October 2022 | Abandon | 25 | 2 | 1 | No | No |
| 16975946 | METHODS AND COMPOSITIONS FOR TREATING BILE DUCT PAUCITY-ASSOCIATED CONDITIONS | August 2020 | December 2022 | Allow | 27 | 1 | 1 | No | No |
| 16990916 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | August 2020 | February 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 16986557 | Nucleic Acid Amplification | August 2020 | January 2023 | Allow | 29 | 1 | 1 | No | No |
| 16963998 | DOUBLE-HELIX OLIGONUCLEOTIDE CONSTRUCT COMPRISING DOUBLE-STRANDED MIRNA AND USE THEREOF | July 2020 | June 2023 | Allow | 35 | 2 | 1 | No | No |
| 16930035 | RNAi Induced Huntingtin Gene Suppression | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16926040 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME TYPE 2 | July 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16961205 | PATTERN RECOGNITION RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | July 2020 | April 2024 | Allow | 45 | 1 | 1 | No | No |
| 16922948 | METHODS AND COMPOSITIONS FOR INCREASED DOUBLE STRANDED RNA PRODUCTION | July 2020 | March 2023 | Allow | 32 | 2 | 0 | No | No |
| 16921390 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | July 2020 | October 2021 | Abandon | 16 | 0 | 1 | No | No |
| 16918239 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | July 2020 | February 2022 | Allow | 19 | 1 | 1 | No | No |
| 16956700 | APTAMER TEMPLATE AND METHOD FOR PREPARING APTAMER BY USING SAME | June 2020 | August 2023 | Abandon | 38 | 2 | 1 | Yes | Yes |
| 16908346 | Influenza-Activated Constructs and Methods of Use Thereof | June 2020 | September 2021 | Allow | 15 | 0 | 1 | Yes | No |
| 16956271 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | June 2020 | August 2022 | Allow | 25 | 1 | 1 | No | No |
| 16955521 | METHODS OF GENETIC MEDIATED ENGINEERING OF RNAi MODELS | June 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16902029 | P38 MAP KINASE INHIBITORS | June 2020 | September 2021 | Allow | 15 | 1 | 1 | No | No |
| 16772574 | HOMOLOGOUS RECOMBINATION VIA TRANSCRIPTIONAL ACTIVATION | June 2020 | November 2023 | Allow | 41 | 1 | 1 | No | No |
| 16770161 | OLIGONUCLEOTIDES, MANUFACTURING METHOD FOR SAME, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | June 2020 | December 2022 | Allow | 30 | 2 | 1 | No | No |
| 16891571 | MOUSE COMPRISING A HUMANIZED TTR LOCUS WITH A BETA-SLIP MUTATION AND METHODS OF USE | June 2020 | September 2023 | Allow | 39 | 1 | 1 | No | No |
| 16767683 | ANTI-CHYMASE APTAMER AND USE FOR SAME | May 2020 | December 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16867603 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES | May 2020 | July 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16857652 | METHODS AND COMPOSITIONS FOR ENHANCING FUNCTIONAL MYELIN PRODUCTION | April 2020 | February 2021 | Allow | 10 | 2 | 1 | Yes | No |
| 16758624 | DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING ONE OR MORE MIRNA AS A BIOMARKER | April 2020 | May 2023 | Allow | 36 | 2 | 1 | No | No |
| 16758185 | APTAMER AGAINST M.TB MPT51 AND USES THEREOF | April 2020 | December 2022 | Abandon | 32 | 0 | 1 | No | No |
| 16842300 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | April 2020 | March 2021 | Allow | 11 | 1 | 0 | No | No |
| 16650614 | MODULATION OF IMMUNE RESPONSE THROUGH STIMULATOR OF INTERFERON GENES | March 2020 | October 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16824592 | DUAL ACTIVITY SUPER TOXIC RNAi ACTIVE dsRNAs | March 2020 | December 2023 | Allow | 45 | 2 | 1 | No | No |
| 16644151 | SINGLE STRANDED OLIGONUCLEOTIDES INHIBITING ENDOCYTOSIS | March 2020 | February 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16804173 | METHODS FOR DETECTING AND TREATING LOW-VIRULENCE INFECTIONS | February 2020 | January 2022 | Abandon | 22 | 0 | 1 | No | No |
| 16640521 | TARGET SEQUENCE SPECIFIC ALTERATION TECHNOLOGY USING NUCLEOTIDE TARGET RECOGNITION | February 2020 | January 2024 | Allow | 47 | 1 | 2 | No | No |
| 16639389 | NUCLEIC ACID APTAMER FOR INHIBITING ACTIVITY OF GENOME-EDITING ENZYME | February 2020 | September 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16639027 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | February 2020 | July 2023 | Allow | 41 | 2 | 2 | No | No |
| 16752742 | XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | January 2020 | December 2021 | Allow | 23 | 1 | 1 | No | No |
| 16773738 | Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals | January 2020 | October 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16634019 | ANTISENSE DRUGS AGAINST CANINE ICAM-1 FOR USE IN THE TREATMENT OF INFLAMMATION OF THE BUCCAL CAVITY | January 2020 | January 2021 | Allow | 12 | 1 | 1 | No | No |
| 16752325 | RNAi Inhibition of Alpha-ENaC Expression | January 2020 | August 2021 | Allow | 19 | 1 | 1 | No | No |
| 16630795 | Gene Editing System and Gene Editing Method | January 2020 | February 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16739245 | Mesothelioma Gene Therapy | January 2020 | November 2023 | Abandon | 46 | 2 | 1 | No | Yes |
| 16732725 | DOUBLE-STRANDED NUCLEIC ACID MOLECULE, DNA, VECTOR, CANCER CELL GROWTH INHIBITOR, CANCER CELL MIGRATION INHIBITOR, AND DRUG | January 2020 | September 2020 | Allow | 8 | 0 | 1 | No | No |
| 16725723 | NOVEL THERAPEUTIC AGENT FOR A LUNG DISEASE AND/OR METHOD FOR SCREENING FOR THE SAME | December 2019 | December 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16723744 | Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals | December 2019 | October 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16718911 | IN VIVO DELIVERY OF OLIGONUCLEOTIDES | December 2019 | October 2021 | Allow | 22 | 1 | 1 | No | No |
| 16716085 | THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME | December 2019 | February 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16622249 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH GAIN-OF-FUNCTION MUTATIONS IN KCNT1 | December 2019 | February 2023 | Allow | 38 | 2 | 1 | No | No |
| 16620700 | LONG NON-CODING RNA IN CANCER | December 2019 | December 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16699944 | MICRO-RNA-155 ENHANCES THE EFFICACY OF DENDRITIC CELL VACCINE FOR CANCER | December 2019 | March 2021 | Allow | 15 | 2 | 0 | No | No |
| 16692928 | REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING | November 2019 | September 2021 | Allow | 22 | 1 | 1 | No | No |
| 16616224 | BCL11A GUIDE DELIVERY | November 2019 | April 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16687525 | SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES | November 2019 | January 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16613732 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | November 2019 | April 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16613322 | COMPOSITIONS AND METHODS FOR NON-ANTIBIOTIC TREATING OF BACTERIAL INFECTIONS BY BLOCKING OR DISRUPTING BACTERIAL GENES INVOLVED IN VIRULENCE OR VIABILITY | November 2019 | August 2021 | Allow | 21 | 1 | 1 | No | No |
| 16612734 | COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES | November 2019 | July 2023 | Allow | 44 | 1 | 1 | Yes | No |
| 16610899 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | November 2019 | April 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16660387 | Methods and means for treating DNA repeat instability associated genetic disorders | October 2019 | November 2021 | Allow | 25 | 2 | 1 | No | No |
| 16606377 | P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION | October 2019 | November 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16604444 | Biomarkers And Targets For Proliferative Diseases | October 2019 | October 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16603771 | TARGETED COMPOSITIONS | October 2019 | April 2022 | Allow | 30 | 1 | 1 | No | No |
| 16500005 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | October 2019 | October 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16499991 | COMPOSITIONS AND METHODS FOR DIFFERENTIAL INDUCTION OF CELL DEATH AND INTERFERON EXPRESSION | October 2019 | November 2022 | Allow | 38 | 2 | 1 | No | No |
| 16498102 | ANTISENSE NUCLEIC ACID FOR INHIBITING BIOSYNTHESIS OF CHONDROITIN SULFATE | September 2019 | June 2022 | Allow | 33 | 2 | 1 | No | No |
| 16497294 | MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON | September 2019 | August 2023 | Allow | 47 | 2 | 2 | No | No |
| 16572101 | EXOSOMES AND MICRO-RIBONUCLEIC ACIDS FOR TISSUE REGENERATION | September 2019 | September 2021 | Allow | 24 | 2 | 1 | No | No |
| 16568387 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | September 2019 | August 2021 | Allow | 23 | 1 | 1 | No | No |
| 16561952 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | September 2019 | October 2020 | Allow | 14 | 1 | 1 | Yes | No |
| 16490494 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | August 2019 | November 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16557043 | TEST KIT FOR DETECTING CONCENTRATION OF CARDIOVASCULAR DISEASE-RELATED BIOMARKER AND CONCENTRATION DETECTION METHOD FOR DETECTING CONCENTRATION OF CARDIOVASCULAR DISEASE-RELATED BIOMARKER | August 2019 | July 2020 | Allow | 10 | 0 | 1 | No | No |
| 16487762 | ANTISENSE OLIGONUCLEIC ACID | August 2019 | October 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16487689 | MATERIALS AND METHODS FOR TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 1 (SCA1) AND OTHER SPINOCEREBELLAR ATAXIA TYPE 1 PROTEIN (ATXN1) GENE RELATED CONDITIONS OR DISORDERS | August 2019 | September 2022 | Allow | 37 | 0 | 1 | Yes | No |
| 16543102 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | August 2019 | July 2021 | Allow | 23 | 1 | 1 | No | No |
| 16542381 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | August 2019 | December 2020 | Allow | 16 | 1 | 0 | Yes | No |
| 16538602 | STABLE TRANSFORMATION OF A POPULATION AND A METHOD OF BIOCONTAINMENT USING HAPLOINSUFFICIENCY AND UNDERDOMINANCE PRINCIPLES | August 2019 | February 2024 | Allow | 55 | 2 | 1 | No | No |
| 16484046 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | August 2019 | March 2022 | Allow | 31 | 0 | 1 | No | No |
| 16477406 | PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION | July 2019 | February 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16509365 | MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF | July 2019 | November 2020 | Abandon | 16 | 0 | 1 | No | No |
| 16457300 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | June 2019 | December 2020 | Allow | 17 | 0 | 2 | Yes | No |
| 16451101 | Antisense oligonucleotides rescue aberrant splicing of ABCA4 | June 2019 | April 2023 | Allow | 45 | 2 | 0 | No | No |
| 16448498 | TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE | June 2019 | September 2021 | Allow | 27 | 2 | 1 | Yes | No |
| 16443705 | METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE USING MICRORNA | June 2019 | August 2021 | Allow | 26 | 1 | 1 | No | No |
| 16443700 | USES FOR PREVENTION OR TREATMENT OF BRAIN DISEASES USING MICRORNA | June 2019 | August 2020 | Allow | 14 | 1 | 1 | No | No |
| 16441811 | LONG NON-CODING RNA USED FOR ANTICANCER THERAPY | June 2019 | May 2021 | Abandon | 23 | 2 | 1 | Yes | No |
| 16436696 | ANTIVIRAL AGENTS | June 2019 | July 2021 | Allow | 25 | 2 | 1 | No | No |
| 16434787 | COMPOSITIONS AND METHODS FOR THE MODULATION OF ADAPTIVE IMMUNITY | June 2019 | November 2023 | Abandon | 53 | 3 | 1 | No | No |
| 16429501 | Compositions and Methods for Inhibiting Gene Expression of Factor XII | June 2019 | August 2020 | Allow | 14 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANGELL, JON E.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ANGELL, JON E works in Art Unit 1635 and has examined 630 patent applications in our dataset. With an allowance rate of 44.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner ANGELL, JON E's allowance rate of 44.9% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ANGELL, JON E receive 1.66 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ANGELL, JON E is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.6% benefit to allowance rate for applications examined by ANGELL, JON E. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 36% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 44.5% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 62.1% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.